Drugs / anti-TRBC1 CAR-T cell therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04828174 | Mar 2021 → Nov 2023 | T-cell leukemia, T-lymphoblastic lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma +1 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Suspended | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-TRBC1 CAR-T cell therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04828174 ↗ |
| Modality | Cell therapy | “CAR-T cell therapy” NCT04828174 ↗ |
| Target | TRBC1 | “CAR-T cell therapy targetting TRBC1” NCT04828174 ↗ |